NotesFAQContact Us
Search Tips
Back to results
Peer reviewed Peer reviewed
Direct linkDirect link
ERIC Number: EJ1003191
Record Type: Journal
Publication Date: 2012-Dec
Pages: 6
Abstractor: As Provided
ISSN: ISSN-0021-9584
Therapeutic Recombinant Monoclonal Antibodies
Bakhtiar, Ray
Journal of Chemical Education, v89 n12 p1537-1542 Dec 2012
During the last two decades, the rapid growth of biotechnology-derived techniques has led to a myriad of therapeutic recombinant monoclonal antibodies with significant clinical benefits. Recombinant monoclonal antibodies can be obtained from a number of natural sources such as animal cell cultures using recombinant DNA engineering. In contrast to most low molecular weight drugs, which are chemically synthesized and their structures are well understood, recombinant monoclonal antibodies are large (e.g., 150 kDa) complex mixtures possessing post-translational modifications. Therapeutic recombinant monoclonal antibodies represent the state-of-the-art of biomedical research and provide effective strategies to treat a number of diseases for which there are no available treatments. The hallmark of a therapeutic monoclonal antibody is to bind to its target antigen (e.g., a cancer cell) with high affinity and specificity and render its destruction. A brief overview of recombinant therapeutic monoclonal antibodies including their structures, productions, and clinical applications is presented. This article is a general tutorial for upper-level pharmacy and premed undergraduate students and graduate students with an introductory biochemistry background. (Contains 3 tables and 2 figures.)
Division of Chemical Education, Inc and ACS Publications Division of the American Chemical Society. 1155 Sixteenth Street NW, Washington, DC 20036. Tel: 800-227-5558; Tel: 202-872-4600; e-mail:; Web site:
Publication Type: Journal Articles; Reports - Descriptive
Education Level: Higher Education
Audience: N/A
Language: English
Sponsor: N/A
Authoring Institution: N/A
Grant or Contract Numbers: N/A